S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.74 (+0.57%)
AAPL   180.52 (-0.50%)
MSFT   408.56 (+0.21%)
META   487.77 (+0.77%)
GOOGL   136.84 (+0.34%)
AMZN   174.91 (+1.01%)
TSLA   200.12 (-0.95%)
NVDA   792.82 (+2.08%)
NIO   5.66 (+4.24%)
AMD   187.42 (+6.16%)
BABA   74.20 (-0.52%)
T   17.03 (+0.41%)
F   12.45 (+1.22%)
MU   89.78 (+0.08%)
CGC   3.32 (-1.19%)
GE   156.08 (+0.30%)
DIS   111.40 (+0.54%)
AMC   4.44 (-11.02%)
PFE   26.88 (-0.59%)
PYPL   60.56 (+0.51%)
XOM   104.62 (+0.29%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.74 (+0.57%)
AAPL   180.52 (-0.50%)
MSFT   408.56 (+0.21%)
META   487.77 (+0.77%)
GOOGL   136.84 (+0.34%)
AMZN   174.91 (+1.01%)
TSLA   200.12 (-0.95%)
NVDA   792.82 (+2.08%)
NIO   5.66 (+4.24%)
AMD   187.42 (+6.16%)
BABA   74.20 (-0.52%)
T   17.03 (+0.41%)
F   12.45 (+1.22%)
MU   89.78 (+0.08%)
CGC   3.32 (-1.19%)
GE   156.08 (+0.30%)
DIS   111.40 (+0.54%)
AMC   4.44 (-11.02%)
PFE   26.88 (-0.59%)
PYPL   60.56 (+0.51%)
XOM   104.62 (+0.29%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.74 (+0.57%)
AAPL   180.52 (-0.50%)
MSFT   408.56 (+0.21%)
META   487.77 (+0.77%)
GOOGL   136.84 (+0.34%)
AMZN   174.91 (+1.01%)
TSLA   200.12 (-0.95%)
NVDA   792.82 (+2.08%)
NIO   5.66 (+4.24%)
AMD   187.42 (+6.16%)
BABA   74.20 (-0.52%)
T   17.03 (+0.41%)
F   12.45 (+1.22%)
MU   89.78 (+0.08%)
CGC   3.32 (-1.19%)
GE   156.08 (+0.30%)
DIS   111.40 (+0.54%)
AMC   4.44 (-11.02%)
PFE   26.88 (-0.59%)
PYPL   60.56 (+0.51%)
XOM   104.62 (+0.29%)
S&P 500   5,083.63 (+0.27%)
DOW   38,979.33 (+0.08%)
QQQ   437.74 (+0.57%)
AAPL   180.52 (-0.50%)
MSFT   408.56 (+0.21%)
META   487.77 (+0.77%)
GOOGL   136.84 (+0.34%)
AMZN   174.91 (+1.01%)
TSLA   200.12 (-0.95%)
NVDA   792.82 (+2.08%)
NIO   5.66 (+4.24%)
AMD   187.42 (+6.16%)
BABA   74.20 (-0.52%)
T   17.03 (+0.41%)
F   12.45 (+1.22%)
MU   89.78 (+0.08%)
CGC   3.32 (-1.19%)
GE   156.08 (+0.30%)
DIS   111.40 (+0.54%)
AMC   4.44 (-11.02%)
PFE   26.88 (-0.59%)
PYPL   60.56 (+0.51%)
XOM   104.62 (+0.29%)

Supernus Pharmaceuticals (SUPN) Earnings Date, Estimates & Call Transcripts

$29.35
-1.73 (-5.57%)
(As of 11:15 AM ET)

Earnings Summary

Upcoming
Earnings Date
May. 14Estimated
Actual EPS
(Feb. 27)
$0.02 Missed By -$0.39
Consensus EPS
(Feb. 27)
$0.41
Skip Charts & View Estimated and Actual Earnings Data

SUPN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

SUPN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Supernus Pharmaceuticals Analyst EPS Estimates

Current Year EPS Consensus Estimate:$1.80 EPS
Next Year EPS Consensus Estimate: $2.12 EPS

SUPN Earnings Date and Information

Supernus Pharmaceuticals last announced its quarterly earnings data on February 27th, 2024. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.41 by $0.39. The business had revenue of $164.30 million for the quarter, compared to the consensus estimate of $155.03 million. Its revenue for the quarter was down 1.8% compared to the same quarter last year. Supernus Pharmaceuticals has generated $0.00 earnings per share over the last year. Earnings for Supernus Pharmaceuticals are expected to grow by 17.78% in the coming year, from $1.80 to $2.12 per share. Supernus Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off prior year's report dates.

Supernus Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/14/2024
Estimated)
------- 
2/27/2024Q4 2023$0.41$0.02($0.39)$0.02$155.03 million$164.30 million    
11/8/2023Q3 2023$0.13($0.29)($0.42)($0.29)$143.39 million$153.88 million      
8/8/2023Q2 2023$0.23($0.02)($0.25)($0.02)$143.63 million$135.56 million    
5/9/2023Q1 2023$0.12$0.29+$0.17$0.29$139.02 million$153.80 million    
2/28/2023Q4 2022$0.73$0.43($0.30)$0.43$180.38 million$167.33 million    
11/8/2022Q3 2022$0.32$0.03($0.29)$0.03$173.22 million$177.35 million
8/4/2022Q2 2022$0.30$0.14($0.16)$0.14$164.23 million$170.10 million      
5/9/2022Q1 2022$0.26$0.43+$0.17$0.43$150.47 million$152.50 million      
4/13/2022Q4 2021-$0.04+$0.04$0.04-$159.05 million  
11/3/2021Q3 2021$0.21$0.40+$0.19$0.40$141.32 million$148.46 million    
8/4/2021Q2 2021$0.17$0.43+$0.26$0.43$135.50 million$141.33 million      
5/5/2021Q1 2021$0.26$0.11($0.15)$0.11$131.77 million$130.93 million  












Supernus Pharmaceuticals Earnings - Frequently Asked Questions

When is Supernus Pharmaceuticals's earnings date?

Supernus Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 14th, 2024 based off last year's report dates. Learn more on SUPN's earnings history.

Did Supernus Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Supernus Pharmaceuticals (NASDAQ:SUPN) missed the analysts' consensus estimate of $0.41 by $0.39 with a reported earnings per share (EPS) of $0.02. Learn more on analysts' earnings estimate vs. SUPN's actual earnings.

How can I listen to Supernus Pharmaceuticals's earnings conference call?

The conference call for Supernus Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Supernus Pharmaceuticals's conference call transcript?

The conference call transcript for Supernus Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Supernus Pharmaceuticals generate each year?

Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded annual revenue of $607.52 million.

How much profit does Supernus Pharmaceuticals generate each year?

Supernus Pharmaceuticals (NASDAQ:SUPN) has a recorded net income of $60.71 million. SUPN has generated $0.00 earnings per share over the last four quarters.

What is Supernus Pharmaceuticals's EPS forecast for next year?

Supernus Pharmaceuticals's earnings are expected to grow from $1.80 per share to $2.12 per share in the next year, which is a 17.78% increase.


More Earnings Resources from MarketBeat

This page (NASDAQ:SUPN) was last updated on 2/29/2024 by MarketBeat.com Staff